BCL2L10 and melanoma: To establish the conditions for IHC analysis of melanoma samples using the PA5-22190 antibody, we determined the antigen recovery method, antibody dilution, and other testing conditions (see Methods) using both positive (liver) and negative (placenta) control tissues that were selected based on BCL2L10 mRNA expression data from the Human Protein Atlas (www.proteinatlas.org).